MX363484B - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa. - Google Patents
Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa.Info
- Publication number
- MX363484B MX363484B MX2015006533A MX2015006533A MX363484B MX 363484 B MX363484 B MX 363484B MX 2015006533 A MX2015006533 A MX 2015006533A MX 2015006533 A MX2015006533 A MX 2015006533A MX 363484 B MX363484 B MX 363484B
- Authority
- MX
- Mexico
- Prior art keywords
- novel compounds
- diacylglycerol acyltransferase
- dgat
- acyltransferase inhibitors
- inhibitors
- Prior art date
Links
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 title abstract 2
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000002404 acyltransferase inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- -1 acyl coenzyme A Chemical compound 0.000 abstract 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005516 coenzyme A Substances 0.000 abstract 1
- 229940093530 coenzyme a Drugs 0.000 abstract 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 230000037221 weight management Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3593DE2012 | 2012-11-23 | ||
| IN750DE2013 | 2013-03-14 | ||
| IN3172DE2013 | 2013-10-25 | ||
| PCT/US2013/071376 WO2014081994A1 (en) | 2012-11-23 | 2013-11-22 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015006533A MX2015006533A (es) | 2015-08-06 |
| MX363484B true MX363484B (es) | 2019-03-21 |
Family
ID=50776577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006533A MX363484B (es) | 2012-11-23 | 2013-11-22 | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150322082A1 (enExample) |
| EP (2) | EP3492474B1 (enExample) |
| JP (1) | JP6279600B2 (enExample) |
| KR (1) | KR102176463B1 (enExample) |
| CN (1) | CN104918620B (enExample) |
| AU (1) | AU2013347843B2 (enExample) |
| BR (1) | BR112015011982A8 (enExample) |
| CA (1) | CA2892304C (enExample) |
| CL (1) | CL2015001397A1 (enExample) |
| CY (1) | CY1121426T1 (enExample) |
| DK (1) | DK2922551T3 (enExample) |
| EA (1) | EA031114B1 (enExample) |
| ES (1) | ES2708626T3 (enExample) |
| HR (1) | HRP20190099T1 (enExample) |
| HU (1) | HUE042483T2 (enExample) |
| IL (1) | IL238835B (enExample) |
| LT (1) | LT2922551T (enExample) |
| ME (1) | ME03315B (enExample) |
| MX (1) | MX363484B (enExample) |
| NZ (1) | NZ630436A (enExample) |
| PE (1) | PE20150967A1 (enExample) |
| PH (1) | PH12015501109A1 (enExample) |
| PL (1) | PL2922551T3 (enExample) |
| PT (1) | PT2922551T (enExample) |
| RS (1) | RS58539B1 (enExample) |
| SG (1) | SG11201503761WA (enExample) |
| SI (1) | SI2922551T1 (enExample) |
| SM (1) | SMT201900230T1 (enExample) |
| UA (1) | UA115079C2 (enExample) |
| WO (1) | WO2014081994A1 (enExample) |
| ZA (1) | ZA201503304B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018052818A (ja) * | 2015-01-28 | 2018-04-05 | 武田薬品工業株式会社 | スルホンアミド化合物 |
| CN109963561A (zh) * | 2016-11-18 | 2019-07-02 | 默沙东公司 | 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100795462B1 (ko) * | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20090076275A1 (en) * | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| KR101919080B1 (ko) * | 2011-05-20 | 2018-11-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
-
2013
- 2013-11-22 EP EP18203369.6A patent/EP3492474B1/en active Active
- 2013-11-22 JP JP2015544141A patent/JP6279600B2/ja not_active Expired - Fee Related
- 2013-11-22 KR KR1020157016270A patent/KR102176463B1/ko not_active Expired - Fee Related
- 2013-11-22 ES ES13856479T patent/ES2708626T3/es active Active
- 2013-11-22 SM SM20190230T patent/SMT201900230T1/it unknown
- 2013-11-22 HR HRP20190099TT patent/HRP20190099T1/hr unknown
- 2013-11-22 SI SI201331321T patent/SI2922551T1/sl unknown
- 2013-11-22 NZ NZ630436A patent/NZ630436A/en not_active IP Right Cessation
- 2013-11-22 UA UAA201506216A patent/UA115079C2/uk unknown
- 2013-11-22 SG SG11201503761WA patent/SG11201503761WA/en unknown
- 2013-11-22 DK DK13856479.4T patent/DK2922551T3/en active
- 2013-11-22 US US14/646,403 patent/US20150322082A1/en not_active Abandoned
- 2013-11-22 PE PE2015000657A patent/PE20150967A1/es unknown
- 2013-11-22 CN CN201380069807.4A patent/CN104918620B/zh not_active Expired - Fee Related
- 2013-11-22 ME MEP-2019-14A patent/ME03315B/me unknown
- 2013-11-22 AU AU2013347843A patent/AU2013347843B2/en not_active Ceased
- 2013-11-22 PT PT13856479T patent/PT2922551T/pt unknown
- 2013-11-22 HU HUE13856479A patent/HUE042483T2/hu unknown
- 2013-11-22 CA CA2892304A patent/CA2892304C/en not_active Expired - Fee Related
- 2013-11-22 WO PCT/US2013/071376 patent/WO2014081994A1/en not_active Ceased
- 2013-11-22 RS RS20190081A patent/RS58539B1/sr unknown
- 2013-11-22 PL PL13856479T patent/PL2922551T3/pl unknown
- 2013-11-22 LT LTEP13856479.4T patent/LT2922551T/lt unknown
- 2013-11-22 MX MX2015006533A patent/MX363484B/es unknown
- 2013-11-22 EP EP13856479.4A patent/EP2922551B1/en active Active
- 2013-11-22 BR BR112015011982A patent/BR112015011982A8/pt active Search and Examination
- 2013-11-22 EA EA201590982A patent/EA031114B1/ru unknown
-
2015
- 2015-05-12 ZA ZA2015/03304A patent/ZA201503304B/en unknown
- 2015-05-14 IL IL238835A patent/IL238835B/en active IP Right Grant
- 2015-05-19 PH PH12015501109A patent/PH12015501109A1/en unknown
- 2015-05-22 CL CL2015001397A patent/CL2015001397A1/es unknown
-
2019
- 2019-01-29 CY CY20191100120T patent/CY1121426T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| SG10201810879VA (en) | Pharmaceutical compounds | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
| PH12016501654A1 (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| WO2014031928A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| IN2013CN01340A (enExample) | ||
| EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MY184553A (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| WO2014031933A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| WO2014031936A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
| IN2015DN01151A (enExample) | ||
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |